Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.44 |
| ▸ | F7 | P08709 | 6/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 9/20 | 0.41 |
| ▸ | F3 | P13726 | 5/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.37 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.37 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.37 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.37 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.37 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.37 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.37 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460646 | 0.93 | F7 (0.49) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL30765440 | 0.89 | F7 (0.39) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL23474447 | 0.88 | NTRK1 (0.48) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL30765736 | 0.87 | PDE2A (0.38) | NTRK1F7F2F3PRSS1 | |
| SCHEMBL23474345 | 0.87 | F2 (0.44) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL23474319 | 0.85 | F2 (0.53) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL23460750 | 0.85 | F2 (0.47) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL23474422 | 0.85 | F2 (0.42) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL23511308 | 0.85 | F2 (0.42) | NTRK1F7NTRK3F2F3 | |
| SCHEMBL23474360 | 0.84 | F2 (0.45) | NTRK1F7NTRK3F2F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | OMEROS CORPORATION | 2021-09-23 | — | — | US | disclosed |
| WO-2021178902-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | OMEROS CORPORATION (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | MASP2, ACE2, MAS1 | NTRK1 4579/4885F7 930/4885NTRK3 4672/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NTRK1 4819/4885F7 4789/4885NTRK3 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.